Advanced

Gene therapy for dopamine replacement in Parkinson's disease.

Björklund, Anders LU ; Björklund, Tomas LU and Kirik, Deniz LU (2009) In Science Translational Medicine 1(2). p.2-2
Abstract
The introduction of L-dopa (L-3,4-dihydroxyphenylalanine) therapy 40 years ago was a revolution in the treatment of patients with Parkinson s disease (PD). With time, however, the shortcomings of oral L-dopa medication became apparent, in particular the appearance of troublesome side effects, expressed as involuntary movements (dyskinesias) that developed over time in many patients. A gene therapy approach, aimed at restoring dopamine synthesis in the affected brain by viral vector delivery of genes that encode the dopamine-synthesizing enzymes, may offer a solution to this problem. Now, a team of French and UK researchers reports promising results in a nonhuman primate model of PD, paving the way for clinical trials of this... (More)
The introduction of L-dopa (L-3,4-dihydroxyphenylalanine) therapy 40 years ago was a revolution in the treatment of patients with Parkinson s disease (PD). With time, however, the shortcomings of oral L-dopa medication became apparent, in particular the appearance of troublesome side effects, expressed as involuntary movements (dyskinesias) that developed over time in many patients. A gene therapy approach, aimed at restoring dopamine synthesis in the affected brain by viral vector delivery of genes that encode the dopamine-synthesizing enzymes, may offer a solution to this problem. Now, a team of French and UK researchers reports promising results in a nonhuman primate model of PD, paving the way for clinical trials of this enzyme-replacement approach. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Science Translational Medicine
volume
1
issue
2
pages
2 - 2
publisher
American Association for the Advancement of Science (AAAS)
external identifiers
  • wos:000277147600002
  • pmid:20368161
  • scopus:76949092638
ISSN
1946-6242
DOI
10.1126/scitranslmed.3000350
language
English
LU publication?
yes
id
56c94388-dc90-4bab-944b-60887490136c (old id 1595589)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20368161?dopt=Abstract
date added to LUP
2010-05-03 16:01:40
date last changed
2017-04-09 04:28:29
@article{56c94388-dc90-4bab-944b-60887490136c,
  abstract     = {The introduction of L-dopa (L-3,4-dihydroxyphenylalanine) therapy 40 years ago was a revolution in the treatment of patients with Parkinson s disease (PD). With time, however, the shortcomings of oral L-dopa medication became apparent, in particular the appearance of troublesome side effects, expressed as involuntary movements (dyskinesias) that developed over time in many patients. A gene therapy approach, aimed at restoring dopamine synthesis in the affected brain by viral vector delivery of genes that encode the dopamine-synthesizing enzymes, may offer a solution to this problem. Now, a team of French and UK researchers reports promising results in a nonhuman primate model of PD, paving the way for clinical trials of this enzyme-replacement approach.},
  author       = {Björklund, Anders and Björklund, Tomas and Kirik, Deniz},
  issn         = {1946-6242},
  language     = {eng},
  number       = {2},
  pages        = {2--2},
  publisher    = {American Association for the Advancement of Science (AAAS)},
  series       = {Science Translational Medicine},
  title        = {Gene therapy for dopamine replacement in Parkinson's disease.},
  url          = {http://dx.doi.org/10.1126/scitranslmed.3000350},
  volume       = {1},
  year         = {2009},
}